HER2-positive Clinical Trials

153 recruitingLast updated: June 18, 2026

There are 153 actively recruiting her2-positive clinical trials across 41 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Beijing, Beijing Municipality, China, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


HER2-positive Trials at a Glance

153 actively recruiting trials for her2-positive are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Phase 2 with 68 trials, with the heaviest enrollment activity in Houston, Beijing, and Boston. Lead sponsors running her2-positive studies include Shu Wang, Sichuan Baili Pharmaceutical Co., Ltd., and H. Lee Moffitt Cancer Center and Research Institute.

Browse her2-positive trials by phase

Treatments under study

About HER2-positive Clinical Trials

Looking for clinical trials for HER2-positive? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2-positive trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2-positive clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 153 trials

Recruiting
Phase 2

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Breast CancerColorectal, CancerLung Cancer+13 more
Brigham and Women's Hospital134 enrolled2 locationsNCT04899908
Recruiting
Not Applicable

Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients

HER2-positive Breast CancerDiarrhea Caused by DrugNeratinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University308 enrolled1 locationNCT06892093
Recruiting
Phase 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled293 locationsNCT06764875
Recruiting
Phase 1

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

HER2-positive Breast Cancer
University of Alabama at Birmingham25 enrolled1 locationNCT04332588
Recruiting

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+3 more
Mayo Clinic230 enrolled1 locationNCT04517838
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting
Phase 2

Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

HER2-positive Breast Cancer
The First Affiliated Hospital of Soochow University124 enrolled1 locationNCT07647263
Recruiting
Phase 1Phase 2

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

HER2-Positive Solid Tumor
Yuhan Corporation147 enrolled19 locationsNCT05523947
Recruiting
Phase 2Phase 3

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

HER2-positive Breast Cancer
Hoffmann-La Roche650 enrolled55 locationsNCT07413939
Recruiting

Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer

HER2-positive Breast Cancer
Centre Paul Strauss9,000 enrolled1 locationNCT04638725
Recruiting
Phase 2

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Breast CancerHER2-positive
M.D. Anderson Cancer Center20 enrolled1 locationNCT05035836
Recruiting
Phase 2

Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

HER2-positive Breast Cancer
Hebei Medical University Fourth Hospital182 enrolled1 locationNCT07635342
Recruiting
Phase 3

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.596 enrolled2 locationsNCT07518173
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 3

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.416 enrolled75 locationsNCT07047365
Recruiting
Not Applicable

Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University20 enrolled1 locationNCT07616440
Recruiting
Phase 1Phase 2

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech36 enrolled1 locationNCT07622940
Recruiting
Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

HER2-positive Metastatic Breast CancerAdvanced/Metastatic Breast Cancer
Sun Yat-sen University57 enrolled1 locationNCT07610720
Recruiting
Phase 2

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

Breast CancerHER2-positive Breast CancerBreast Cancer Stage IV
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07459673